Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS) released its quarterly earnings results on Monday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03), Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 78.25%. The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. During the same quarter last year, the firm posted ($0.31) EPS.

Cellectis Stock Down 2.3 %

NASDAQ CLLS traded down $0.04 during trading on Thursday, hitting $1.73. 51,171 shares of the stock traded hands, compared to its average volume of 48,834. Cellectis has a 12-month low of $1.73 and a 12-month high of $3.77. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92. The firm has a 50-day simple moving average of $2.07 and a 200-day simple moving average of $2.27.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CLLS shares. StockNews.com initiated coverage on shares of Cellectis in a research report on Tuesday. They set a “sell” rating for the company. Barclays lowered their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.